ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AEZS Stock Price » AEZS Stock News

Aeterna Zentaris Share News

 Aeterna Zentaris (mm) Stock Price
AEZS Stock Price
 Aeterna Zentaris (mm) Stock Chart
AEZS Stock Chart
 Aeterna Zentaris (mm) Stock News
AEZS Stock News
 Aeterna Zentaris (mm) Company Information
AEZS Company Information
 Aeterna Zentaris (mm) Stock Trades
AEZS Stock Trades

Keryx Biopharma Shares Rally On Orphan-Drug Designation

DOW JONES NEWSWIRES Keryx Biopharmaceuticals Inc. (KERX) said the U.S. Food and Drug Administration has given orphan-drug designation to perifosine, a treatment for cancer including neuroblastoma, or cancer of the nervous system in infants. Shares of the biopharmaceutical company jumped 13% to $4.04 in recent trading, while U.S.-traded shares of Keryx's Canadian partner Aeterna Zentaris Inc. (AEZ.T, AEZS) were recently up 10% to $1.20. The designation was announced three months after the drug received fast-track status, which authorizes an expedited review for drugs that treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. "The Orphan Drug designation is an important component of our development plan for perifosine in neuroblastoma, an indication where no FDA-approved therapies currently exist," said Chief Executive Ron Bentsur. The Orphan Drug Act provides incentives to create therapies for so-called orphan diseases--those that affect fewer than 200,000 Americans. There are about 7,000 such maladies, most of them serious, that have few or no drugs to treat them. Getting an orphan-drug designation opens the door to incentives once the FDA approves a medicine for sale in the U.S., including seven years' marketing exclusivity and tax breaks. Bentsur said the company is exploring the next steps for the development, which "we hope, ultimately, could provide a new treatment option for children and infants" suffering with the illnesses. Perifosine also is in Phase 3 clinical trial for treating refractory advanced colon cancer and multiple myeloma, as well as in Phase 1 and Phase 2 trials for several other tumor types. -By Jodi Xu, Dow Jones Newswires; 212-416-3037;

Stock News for Aeterna Zentaris (AEZS)
02/12/201608:07:35Amended Statement of Ownership (sc 13g/a)
02/01/201617:33:00Aeterna Zentaris to Participate in 18th Annual BIO CEO & Investor...
01/29/201608:30:00Aeterna Zentaris Announces Appointments to Board of Directors
01/26/201608:30:00Aeterna Zentaris Files International Patent Application for Novel...
01/25/201608:30:00Aeterna Zentaris Announces Additional Market Purchases of Common...
01/19/201608:30:00Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators...
01/14/201615:24:03Amended Statement of Ownership (sc 13g/a)
01/13/201615:00:00Aeterna Zentaris Affirms Focus on Targeted Oncology During 2016...
01/12/201617:08:33Amended Registration Statement for Securities of Certain Canadian...
12/30/201516:06:00Aeterna Zentaris Announces Filing of Preliminary Base Shelf Prospectus
12/30/201512:07:36Appointment of Agent for Service of Process and Undertaking (f-x)
12/30/201511:36:19Registration Statement for Securities of Certain Canadian Issuers...
12/15/201514:09:24Report of Foreign Issuer (6-k)
12/14/201514:17:49Report of Foreign Issuer (6-k)
12/14/201512:30:00Aeterna Zentaris Announces Closing of US$16.65 Million Public...
12/09/201517:26:15Voluntary Supplemental Material Filed Pursuant to Section 11(a...
12/09/201512:39:55Report of Foreign Issuer (6-k)
12/09/201508:25:00Aeterna Zentaris Announces Pricing of US$16.65 Million Public...
12/09/201506:08:30Report of Foreign Issuer (6-k)
12/09/201506:05:49Voluntary Supplemental Material Filed Pursuant to Section 11(a...

Aeterna Zentaris and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations